 |
15 Diseases |  |
3 Trials |
|
3 Trials |  |
9 News |  |
- || Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
P2 data, Journal: Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy. (Pubmed Central) - Sep 26, 2023
P2
Besides the development of an epiretinal membrane in one patient, the intravitreal application of allogeneic BM-MSCs appeared to be intraocularly well tolerated. Consequently, not only NA-AION but also BM-MSCs deserve more clinical investigational resources and a larger randomized multicenter trial that would provide stronger evidence both about safety and the potential therapeutic efficacy of intravitreally injected allogeneic BM-MSCs in acute NA-AION.
- || Trial completion: Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM (clinicaltrials.gov) - Mar 15, 2023
P1/2, N=36, Completed, Sponsor: Medipost Co Ltd.
Consequently, not only NA-AION but also BM-MSCs deserve more clinical investigational resources and a larger randomized multicenter trial that would provide stronger evidence both about safety and the potential therapeutic efficacy of intravitreally injected allogeneic BM-MSCs in acute NA-AION. Unknown status --> Completed
- | Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
New trial: Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM® (clinicaltrials.gov) - Jul 8, 2021
P=N/A, N=9, Not yet recruiting, Sponsor: Samsung Medical Center
- || Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
Trial completion, Trial completion date, Trial primary completion date: Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease (clinicaltrials.gov) - Aug 28, 2020
P1/2, N=46, Completed, Sponsor: Medipost Co Ltd.
Unknown status --> Completed Recruiting --> Completed | Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
- | Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
New P1/2 trial, P1 data, P1/2 data: Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial. (clinicaltrials.gov) - Jun 1, 2017
P1/2, N=45, Recruiting, Sponsor: Medipost Co Ltd.
- Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
Trial primary completion date: Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease (clinicaltrials.gov) - Apr 20, 2017
P1/2, N=45, Recruiting, Sponsor: Medipost Co Ltd.
Recruiting --> Completed | Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial primary completion date: Feb 2018 --> Jul 2019
- Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
Trial primary completion date: Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease (clinicaltrials.gov) - Jan 18, 2016
P1/2, N=42, Recruiting, Sponsor: Medipost Co Ltd.
Trial primary completion date: Feb 2018 --> Jul 2019 Trial primary completion date: Dec 2015 --> Feb 2018
- | Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
Enrollment open: Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease (clinicaltrials.gov) - Apr 9, 2015
P1/2, N=40, Recruiting, Sponsor: Medipost Co Ltd.
Trial primary completion date: Dec 2015 --> Feb 2018 Not yet recruiting --> Recruiting
- | Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
New P1/2 trial: Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 2, 2014
P1/2, N=40, Not yet recruiting, Sponsor: Medipost Co Ltd.
- | Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
New P1 trial, P1 data: The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD (clinicaltrials.gov) - Sep 27, 2012
P1, N=14, Recruiting, Sponsor: Duk Lyul Na
- Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
Trial completion: The Safety and The Efficacy Evaluation of NEUROSTEM (clinicaltrials.gov) - Apr 18, 2012
P1, N=9, Completed, Sponsor: Medipost Co Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed